On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community ...

Rajshekhar Chakraborty, MD, discusses the safety and tolerability of linvoseltamab with carfilzomib when used for the ...

The Food and Drug Administration (FDA) granted a priority review for a Biologics License Application (BLA) to linvoseltamab for the treatment of adults with relapsed or refractory multiple myeloma who ...

Linvoseltamab combined with carfilzomib showed strong responses in R/R MM All treated patients (n=23) had previous exposure to PIs and more than half (n=12) were refractory to at least one PI ...

And just to put that in context, with the linvoseltamab monotherapy, we saw about 50% complete response or better. So, here, there's an upgrade of about 26-76% complete response or better.

PURPOSEWe present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in ...

Regeneron is committed to working closely with the third-party fill/finish manufacturer and the FDA to bring linvoseltamab to appropriate patients with R/R MM as quickly as possible, which is ...

Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate local T-cell ...

Regeneron: CHMP Recommends Conditional Marketing Authorization Of Linvoseltamab February 28, 2025 — 07:22 am EST Written by RTTNews.com for RTTNews -> ...

Among enrolled patients (n=24), 6 received linvoseltamab at 100 mg and 18 at 200 mg before initiating bortezomib. More than half were refractory to PIs, including 58% to carfilzomib and 13% to ...